Evidence map›Paper›PMID 42834406›Full record

ReviewOrphanet journal of rare diseases2026

Hyperphagia in Prader-Willi syndrome: linking hypothalamic dysfunction to clinical assessment and management across the lifespan.

Maithé Tauber, Gwenaëlle Diene, Christine Poitou, Charlotte Höybye, Evelien F Gevers, Anthony P Goldstone, Andrea M Haqq, Yoon Hi Cho, Ashley H Shoemaker, Janice L Forster and 9 more

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maithé TauberCentre de Référence Maladies Rares PRADORT (syndrome de PRADer-Willi et autres Obésités Rares avec Troubles du comportement alimentaire) and European Reference Network on Rare Endocrine Conditions (Endo-ERN), Hôpital des Enfants, CHU Toulouse, Université Toulouse III, Toulouse, France. tauber.mt@chu-toulouse.fr.
Gwenaëlle DieneCentre de Référence Maladies Rares PRADORT (syndrome de PRADer-Willi et autres Obésités Rares avec Troubles du comportement alimentaire) and European Reference Network on Rare Endocrine Conditions (Endo-ERN), Hôpital des Enfants, CHU Toulouse, Université Toulouse III, Toulouse, France.
Christine PoitouSorbonne Université, Assistance Publique-Hôpitaux de Paris, Department of Nutrition and European Reference Network on Rare Endocrine Conditions (Endo-ERN), Pitié-Salpêtrière Hospital, Paris, France.
Charlotte HöybyeDepartment of Endocrinology and Department of Molecular Medicine and Surgery and European Reference Network on Rare Endocrine Conditions (Endo-ERN), Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
Evelien F GeversCentre for Endocrinology, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
Anthony P GoldstonePsychoNeuroEndocrinology Research Group, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
Andrea M HaqqUniversity of Alberta, Alberta, Canada.
Yoon Hi ChoThe Children's Hospital at Westmead, Sydney, Australia.
Ashley H ShoemakerVanderbilt University Medical Center, Nashville, TN, USA.
Janice L ForsterPittsburgh Partnership, Pittsburgh, PA, USA.
Anthony HollandDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Stephanie BrownDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Laura de GraaffDutch Center of Reference for Prader-Willi Syndrome and European Reference Network on Rare Endocrine Conditions (Endo-ERN), Rotterdam, The Netherlands.
Ann ManzardoUniversity of Kansas Medical Center, Kansas City, KS, USA.
Assumpta CaixàsEndocrinology and Nutrition Department, Consorci Corporació Sanitària Parc Taulí. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Medicine Department Universitat Autònoma de Barcelona, Sabadell, Spain.
Elena G BochukovaBlizard Institute, Queen Mary University, London, UK.
Paula MaguireSoleno Therapeutics Europe, a Neurocrine Biosciences Company, Dublin, Ireland.
Dairine DempseySoleno Therapeutics Europe, a Neurocrine Biosciences Company, Dublin, Ireland.
Jennifer MillerDivision of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder characterised by hypothalamic dysfunction and profound dysregulation in hunger and appetite regulation, endocrine function, metabolism and behaviour. Hyperphagia is a defining clinical feature and a major contributor to morbidity, mortality and caregiver burden. Increasing evidence suggests that hyperphagia in PWS represents a multidimensional disorder rather than excessive appetite alone.

resultsIn December 2024, an international meeting of clinical and scientific experts was convened in Toulouse, France, to explore current understanding of hyperphagia in PWS, challenges in assessment, and evolving approaches to management across the lifespan. Although not a formal consensus process, several consistent themes emerged. These included limitations of existing assessment tools, the need for multidimensional evaluation (including use of instruments such as the Hyperphagia Questionnaire and Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The central role of structured food environments, and vulnerabilities during transition to adult care were also identified as key themes. Experts emphasised that hyperphagia reflects interactions between impaired satiety signalling, activation in reward neurocircuitry, autonomic dysfunction and environmental factors. Management therefore requires integrated biological, behavioural and environmental approaches. While food security and structured support remain foundational, emerging pharmacological therapies may complement multidisciplinary care and reduce caregiver burden.

conclusionsHyperphagia in PWS should be conceptualised as a complex, multidimensional disorder requiring comprehensive assessment and integrated management. Future priorities include development of additional validated outcome measures, identification of biomarkers, and care models that better align mechanistic insights with real-world clinical practice.

Indexed as

HyperphagiaHypothalamusPrader-Willi SyndromeHumans15q11-13Genomic imprinting disorderHyperphagiaHypothalamic dysfunctionNeurobehavioral-metabolic disorderNeurodevelopmental disorderObesityPrader-Willi syndrome

Identifiers

PMID42834406
PMCPMC13640150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.